Heliyon (Apr 2024)

Preclinical characterization of Pan-NKG2D ligand-binding NKG2D receptor decoys

  • Peter B. Rupert,
  • Matthew Buerger,
  • Emily J. Girard,
  • Marie Frutoso,
  • Don Parrilla,
  • Kevin Ng,
  • Theodore Gooley,
  • Veronika Groh,
  • Roland K. Strong

Journal volume & issue
Vol. 10, no. 7
p. e28583

Abstract

Read online

NKG2D and its ligands are critical regulators of protective immune responses controlling infections and cancer, defining a crucial immune signaling axis. Current therapeutic efforts targeting this axis almost exclusively aim at enhancing NKG2D-mediated effector functions. However, this axis can drive disease processes when dysregulated, in particular, driving stem-like cancer cell reprogramming and tumorigenesis through receptor/ligand self-stimulation on tumor cells. Despite complexities with its structure and biology, we developed multiple novel engineered proteins that functionally serve as axis-blocking NKG2D “decoys” and report biochemical, structural, in vitro, and in vivo evaluation of their functionality.

Keywords